| |
Tuesday, February 20, 2024 |10am ET / 7am PT Join us for this deep dive into the strategic transformation of research and development (R&D) companies. Industry experts will discuss key takeaways from Clarivate's 2024 Drugs to Watch report, providing a roadmap for marrying scientific excellence with market access acumen to drive transformative change for the benefit of patients. Register now. 
|
|
| By Ben Adams,Nick Paul Taylor Every year, we tap Evaluate’s annual preview report to assess the biggest potential new drugs of the year ahead. Typically, major pharmaceutical and biotechnology companies are featured, each presenting potential blockbuster launches. In 2024, however, things are set to play out a little differently. |
|
|
|
By Fraiser Kansteiner Come mid-February, Pfizer will lay off some 52 employees at a facility in South San Francisco, according to a recent Worker Adjustment and Retraining Notification Act alert. The site is the former headquarters of Global Blood Therapeutics. |
By Gabrielle Masson Pfizer is trimming its pipeline (and team), discarding three assets after R&D spending dropped 24% in the last quarter of 2023. |
By Angus Liu Merck’s unique approval for Keytruda as a postsurgerical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can extend patients’ lives. This comes just as the drug’s rival, Bristol Myers Squibb’s Odpivo, chalked up another trial failure. |
By Max Bayer,Gabrielle Masson Coming off one of the worst years for IPOs in recent history, two new upsized IPOs have offered a stretching ray of hope that 2024 may not be so bad after all. |
By Andrea Park The Innovative Science and Technology Approaches for New Drugs pilot was designed to create a new pathway to FDA review for novel tools that may not fit into currently existing routes of evaluation, but that could potentially improve the development of new drugs. |
By Fraiser Kansteiner New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. federal funding has sent shares tumbling in recent days. WuXi Bio, for its part, says it's not affiliated with the military in China. |
By Eric Sagonowsky Biogen is discontinuing its first Alzheimer's disease therapy, Aduhelm, after walking a rocky path. The company is taking a $60 million charge, halting sales and terminating a confirmatory trial. |
By Joseph Keenan Clinical trial specialist Science 37 has agreed to be acquired by telehealth and diagnostics provider eMed in an all-cash tender offer valued at approximately $38 million. |
By Helen Floersh Researchers have successfully used chimeric antigen receptor T (CAR T) cells to prevent some signs of aging in young mice and reverse them in old ones, building on the case for the therapy’s place in longevity research and regenerative medicine. |
By Nick Paul Taylor Pharma watchers know Sanofi has changed how it presents itself to the world. Under CEO Paul Hudson, Sanofi has pitched itself as humble, authentic, a bit unconventional—and changed its branding to match. But people in the wider world? Well, reaching them poses a different challenge. Sanofi’s attempt to rise to that challenge is supported by a once-in-a-lifetime opportunity: a Summer Olympics in France. |
Fierce podcasts Don’t miss an episode |
| This week on “Podnosis,” we rewind to January 2019 when Fierce Healthcare unveiled its inaugural Fierce 15, spotlighting 15 private companies engaged in pioneering work and making waves in healthcare innovation. In this episode, we reconnect with leaders from two of those companies: Cityblock Health and Civica Rx. |
|
|---|
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Any EHR provider delivering a quality point-of-care marketing solution should be able to answer these seven questions. Sponsored by: Veradigm |
| |
|
